Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
Key Points
Key Points
- Multiple studies of both chemotherapy and endocrine therapy have shown that neoadjuvant treatment can increase the likelihood of breast-conserving surgery.
- The CTNeoBC pooled analysis of neoadjuvant breast cancer clinical trials published in 2014 confirmed that achievement of a pathologic complete response (pCR) with neoadjuvant treatment was prognostic.
- It also showed that the association between pCR and outcomes was strongest in patients with triple negative and human epidermal growth factor receptor 2 (HER2)-positive disease.
- Optimal therapy for breast cancer is driven by subtype.
Treatment
...eatment...
...tion from 2022 Guideline Rapid Recommend...
...with T1cN1-2 or T2-4N0 (stage II or III...
...andidates
...uvant chemotherapy is the treatment of choice for...
...logy, grade, stage and estrogen, prog...
...oadjuvant systemic therapy should be offere...
...oadjuvant systemic therapy may be offered to red...
...patients for whom a delay in surgery i...
Measuring Response
...asuring Response...
...ing neoadjuvant therapy should be monitored...
...tissue-based biomarkers should not be used for...
...as absence of invasive disease in breast and...
Recommended Regimens for Patients with TNBC
...ecommended Regimens for Patients with...
...ith TNBC who have clinically node positive and/...
...nts with cT1a or cT1bN0 TNBC should no...
...tin may be offered as part of a neoadjuv...
...ufficient evidence to recommend rou...
Recommended Neoadjuvant Treatment for Patients with HER2-negative/HR-positive Breast Cancer
...ed Neoadjuvant Treatment for Patien...
...uvant chemotherapy can be used instead of adjuv...
...or postmenopausal patients with HR+, HER2-negativ...
...r premenopausal patients with HR+, HER2-neg...
Recommended Neoadjuvant Treatment for Patients with HER2-Positive Disease
...Neoadjuvant Treatment for Patients...
...with node-positive or high-risk node-negative, H...
...ents with T1a N0 and T1b N0, HER2+ disease shou...